PTAB Axes AbbVie Unit's Cancer Drug Patent As Invalid

The Patent Trial and Appeal Board has found claims in a patent owned by AbbVie's Pharmacyclics unit related to its cancer drug Imbruvica were invalid, the latest in a larger intellectual...

Already a subscriber? Click here to view full article